NovoCure (NVCR) Capital Expenditures (2014 - 2026)

NovoCure has disclosed Capital Expenditures across 13 years of filings, most recently posting $5.2 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $5.2 million, down 51.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.2 million (down 49.17% YoY), and the FY2025 annual result was $26.6 million, down 37.82% from the prior year.
• Capital Expenditures came in at $5.2 million for Q1 2026 at NovoCure, up from $4.9 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $11.8 million in Q1 2024 to a low of $4.1 million in Q2 2022.
• The 5-year median for Capital Expenditures is $6.4 million (2022), against an average of $7.2 million.
• Across the five-year window, Capital Expenditures tumbled 54.95% in 2022 and jumped 93.56% in 2024, its largest moves.
• NovoCure's Capital Expenditures stood at $6.4 million in 2022, then gained by 6.06% to $6.8 million in 2023, then soared by 31.1% to $8.9 million in 2024, then sank by 45.25% to $4.9 million in 2025, then advanced by 5.23% to $5.2 million in 2026.
• The last three Capital Expenditures figures came in at $5.2 million (Q1 2026), $4.9 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.